Stu has passionately dedicated the majority of his career to advancing care for people living with cancer. He has more than two decades of experience successfully shaping and launching oncology products to deliver innovative therapies to the people who need them. He is currently Chief Commercial Officer at IDEAYA Biosciences, with responsibility for building and leading the company’s global commercialization efforts for their broad pipeline of precision medicines.

Prior to joining IDEAYA, Stu worked as the Vice President and Oncology Business Unit head at Gilead Sciences, where he successfully built a leading oncology commercial organization, delivering multiple successful launches for Trodelvy in breast and bladder cancers. Before Gilead, Stu held leadership positions of increasing responsibility across a range of functions at Bristol Myers Squibb [BMS] where he built, led, and transformed commercial teams to deliver outstanding execution and successful launches. Stu started his professional career in healthcare consulting at Trinity, where he led project teams to advance patient care.

Stu holds a bachelor’s degree from Harvard University and an MBA from the Stanford University Graduate School of Business.